BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2020 12:27:09 PM | Browse: 485 | Download: 836
 |
Received |
|
2020-07-02 16:22 |
|
Peer-Review Started |
|
2020-07-02 16:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-10-23 21:16 |
|
Revised |
|
2020-11-01 12:25 |
|
Second Decision |
|
2020-11-11 09:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-12 17:01 |
|
Articles in Press |
|
2020-11-12 17:01 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-11-24 07:31 |
|
Typeset the Manuscript |
|
2020-12-16 06:57 |
|
Publish the Manuscript Online |
|
2020-12-18 12:27 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Pablo Gajate, Javier Torres-Jiménez, Carolina Bueno-Bravo and Felipe Couñago |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Pablo Gajate, MD, Staff Physician, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Ctra. de Colmenar Viejo km. 9100, Madrid 28034, Spain. pgajateborau@gmail.com |
| Key Words |
Metastatic urothelial carcinoma; Immune checkpoint inhibitors; Avelumab; JAVELIN Bladder 100; FGFR inhibitors; ASCO 2020 |
| Core Tip |
The landscape of urothelial carcinoma treatment has changed significantly in the last 5 years. Several drugs with different mechanism of action have emerged as new therapeutic opportunities. At ASCO 2020 avelumab, an immune checkpoint inhibitor, was evaluated as maintenance therapy in the JAVELIN Bladder 100 trial: This was the first clinical trial that improved overall survival in frontline of metastatic setting since the 80s. Moreover, new drugs and combinations strategies have shown its potential role as new therapeutic alternatives to increase survival in this poor prognosis disease. |
| Publish Date |
2020-12-18 12:27 |
| Citation |
Gajate P, Torres-Jiménez J, Bueno-Bravo C, Couñago F. Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. World J Clin Oncol 2020; 11(12): 976-982 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i12/976.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i12.976 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
